Abstract
Stressful life events and dysfunctional Hypothalamic Pituitary Adrenal (HPA) axis have been implicated in the pathogenesis of psychiatric disorders, including anxiety disorders.
This paper attempts to review the existing literature on childhood traumata, recent life events, HPA axis functioning and their relationship in Post-Traumatic Stress Disorder, Panic Disorder, Generalized Anxiety Disorder, Obsessive Compulsive Disorder and Social Phobia. Preclinical and clinical models will be analyzed. Stressful life events seem to have a role in the onset and in the course of these disorders and HPA axis abnormalities have been reported in almost all anxiety disorders. The hypothesis that early stressful life events may provoke alterations of the stress response and thus of the HPA axis, that can endure during adulthood, predisposing individuals to develop psychopathology, will be evaluated.Keywords: Animal models, anxiety disorders, childhood traumata, cortisol, Hypothalamic Pituitary Adrenal axis, life events, stress response, vulnerability.
Current Pharmaceutical Design
Title:The Role of Life Events and HPA Axis in Anxiety Disorders: A Review
Volume: 18 Issue: 35
Author(s): Carlo Faravelli, Carolina Lo Sauro, Lorenzo Lelli, Francesco Pietrini, Lisa Lazzeretti, Lucia Godini, Laura Benni, Giulia Fioravanti, Gabriela Alina Talamba, Giovanni Castellini and Valdo Ricca
Affiliation:
Keywords: Animal models, anxiety disorders, childhood traumata, cortisol, Hypothalamic Pituitary Adrenal axis, life events, stress response, vulnerability.
Abstract: Stressful life events and dysfunctional Hypothalamic Pituitary Adrenal (HPA) axis have been implicated in the pathogenesis of psychiatric disorders, including anxiety disorders.
This paper attempts to review the existing literature on childhood traumata, recent life events, HPA axis functioning and their relationship in Post-Traumatic Stress Disorder, Panic Disorder, Generalized Anxiety Disorder, Obsessive Compulsive Disorder and Social Phobia. Preclinical and clinical models will be analyzed. Stressful life events seem to have a role in the onset and in the course of these disorders and HPA axis abnormalities have been reported in almost all anxiety disorders. The hypothesis that early stressful life events may provoke alterations of the stress response and thus of the HPA axis, that can endure during adulthood, predisposing individuals to develop psychopathology, will be evaluated.Export Options
About this article
Cite this article as:
Faravelli Carlo, Lo Sauro Carolina, Lelli Lorenzo, Pietrini Francesco, Lazzeretti Lisa, Godini Lucia, Benni Laura, Fioravanti Giulia, Alina Talamba Gabriela, Castellini Giovanni and Ricca Valdo, The Role of Life Events and HPA Axis in Anxiety Disorders: A Review, Current Pharmaceutical Design 2012; 18(35) . https://dx.doi.org/10.2174/138161212803530907
DOI https://dx.doi.org/10.2174/138161212803530907 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |

- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
- Forthcoming Thematic Issues
Related Articles
-
Optimized High-Yield Purification of Obesity-Associated Melanocortin 4 Receptor
Protein & Peptide Letters Recent Advances in the Understanding of Sepsis-Induced Alterations in the Neuroendocrine System
Endocrine, Metabolic & Immune Disorders - Drug Targets Short, but Highly Concentrated, Direct Inhalations of Essential Oil Molecules Improve Poor Sleep Quality: A Natural History Controlled, Withingroup, Self-administration Field Pilot Study
Current Psychopharmacology Cyclooxygenases in the Central Nervous System: Implications for Treatment of Neurological Disorders
Current Pharmaceutical Design Sympathetic Nervous System Dysfunction in Multiple Sclerosis, Linking Neurodegeneration to a Reduced Response to Therapy
Current Pharmaceutical Design Neuroprotection Abilities of Cytosolic Phospholipase A2 Inhibitors in Kainic acid-induced Neurodegeneration
Current Drug Targets - Cardiovascular & Hematological Disorders Dissecting Insulin Signaling Pathways: Individualised Therapeutic Targets for Diagnosis and Treatment of Insulin Resistant States
Endocrine, Metabolic & Immune Disorders - Drug Targets Fighting Alzheimer's Disease and Type 2 Diabetes: Pathological links and Treatment Strategies
CNS & Neurological Disorders - Drug Targets Evaluation of Pharmacological Treatment Strategies in Traumatic Brain Injury
Current Pharmaceutical Design Effects of Thyroid Hormones and their Metabolites on Learning and Memory in Normal and Pathological Conditions
Current Drug Metabolism Patent on Biomarkers in Medical Research: A Focus on Neuropsychiatric Disorders
Recent Patents on Biomarkers Serotonin and its Receptors in the Human CNS with New Findings - A Mini Review
Current Medicinal Chemistry Chronopharmaceuticals: Hype or Future of Pharmaceutics
Current Pharmaceutical Design Adiposity and the Gut - The Role of Gut Hormones
Current Nutrition & Food Science Role of the APP Non-Amyloidogenic Signaling Pathway and Targeting α-Secretase as an Alternative Drug Target for Treatment of Alzheimers Disease
Current Medicinal Chemistry Discovery of Novel Regulatory Peptides by Reverse Pharmacology: Spotlight on Chemerin and the RF-amide Peptides Metastin and QRFP
Current Protein & Peptide Science Proteome Adjustments Post Gradual Hypoxic Stress in Barilius bendelisis: Insights into Adaptive Strategies of a Hill Stream Cyprinid
Current Proteomics The CRF1 Receptor, a Novel Target for the Treatment of Depression, Anxiety, and Stress-Related Disorders
CNS & Neurological Disorders - Drug Targets The Hypothalamic-Pituitary-Adrenal Axis: What can it Tell us About Stressors?
CNS & Neurological Disorders - Drug Targets 3,5-diiodo-L-thyronine: A Possible Pharmacological Agent?
Current Drug Delivery